Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 3, 2014, Pages 256-268

  Kypreos, Kyriakos E ^a,b   Zafirovic, Sonja ^c   Petropoulou, Peristera Ioanna ^a   Bjelogrlic, Predrag ^d   Resanovic, Ivana ^c   Traish, Abdul ^b   Isenovic, Esma R ^c  

^a UNIVERSITY OF PATRAS   (Greece)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

cardiovascular diseases; endothelial nitric oxide synthase; estradiol; estrogen receptor; high density lipoprotein

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL RESPIRATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHEAR STRESS; THROMBOCYTE FUNCTION; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; METABOLISM; MUSCLE CONTRACTION; MUSCLE RELAXATION; PHYSIOLOGY; SMOOTH MUSCLE FIBER;

ANIMALS; CHOLESTEROL, HDL; ESTRADIOL; HUMANS; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, ESTROGEN;

EID: 84898962124     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413513499     Document Type: Article

References (178)

1. Simoncini T, Fornari L, Mannella P, et al. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids. 2002 ; 67 (12). 935-939
2. Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr Opin Obstet Gynecol. 2000 ; 12 (3). 181-187
3. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 ; 340 (23). 1801-1811
4. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012 ; 135 (1). 54-70
5. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002 ; 89 (12A). 12E - 17E
6. Blum A, Koh K, Cannon RO. CME paper: hormone replacement therapy for prevention or treatment of atherosclerosis in postmenopausal women: promises, controversies, and clinical trials. Am J Geriatr Cardiol. 2000 ; 9 (2). 81-88
7. Di Cesare Mannelli L, Nistri S, Mazzetti L, Bani D, Feil R, Failli P. Altered nitric oxide calcium responsiveness of aortic smooth muscle cells in spontaneously hypertensive rats depends on low expression of cyclic guanosine monophosphate-dependent protein kinase type I. J Hypertens. 2009 ; 27 (6). 1258-1267
8. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995 ; 9 (13). 1319-1330
9. Bakshi CS, Singh VP, Malik M, Singh RK. Sharma B. 55 kb plasmid and virulence-associated genes are positively correlated with Salmonella enteritidis pathogenicity in mice and chickens. Vet Res Commun. 2003 ; 27 (6). 425-432
10. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 ; 333 (1-2). 191-201
11. Soskic SS, Dobutovic BD, Sudar EM, et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc Med J. 2011 ; 5: 153-163
12. Rhodes P, Leone AM, Francis PL, Struthers AD, Moncada S, Rhodes PM. [corrected to Rhodes P]. The l-arginine: nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun. 1995 ; 209 (2). 590-596
13. Mandusic V, Radak D, Markicevic M, et al. Role of estrogen and estrogen receptors in cancer pathology. Endocrinol Stud. 2011 ; 1 (1). 19-23
14. Vassalle C, Simoncini T, Chedraui P, Perez-Lopez FR. Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol. 2012 ; 28 (9). 746-751
15. Ahnstedt H, Cao L, Krause DN, et al. Male-female differences in upregulation of vasoconstrictor responses in human cerebral arteries. PLoS One. 2013 ; 8 (4). e62698
16. Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemiology. Stroke. 2009 ; 40 (4). 1082-1090
17. Akishita M, Yu J. Hormonal effects on blood vessels. Hypertens Res. 2012 ; 35 (4). 363-369
18. Turtzo LC, McCullough LD. Sex-specific responses to stroke. Future Neurol. 2010 ; 5 (1). 47-59
19. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr Rev. 1999 ; 20 (3). 358-417
20. Wu KL, Chen CH, Shih CD. Nontranscriptional activation of PI3K/Akt signaling mediates hypotensive effect following activation of estrogen receptor beta in the rostral ventrolateral medulla of rats. J Biomed Sci. 2012 ; 19 (1). 76
21. Novensa L, Selent J, Pastor M, Sandberg K, Heras M, Dantas AP. Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17{beta}-estradiol. Hypertension. 2010 ; 56 (3). 405-411
22. Koricanac G, Tepavcevic S, Zakula Z, Milosavljevic T, Stojiljkovic M, Isenovic ER. Interference between insulin and estradiol signaling pathways in the regulation of cardiac eNOS and Na(+)/K(+)-ATPase. Eur J Pharmacol. 2011 ; 655 (1-3). 23-30
23. Koricanac G, Milosavljevic T, Stojiljkovic M, et al. Impact of estradiol on insulin signaling in the rat heart. Cell Biochem Funct. 2009 ; 27 (2). 102-110
24. Simoncini T, Varone G, Fornari L, et al. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology. 2002 ; 143 (6). 2052-2061
25. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J Biol Chem. 2005 ; 280 (20). 19704-19710
26. Nathan L, Pervin S, Singh R, Rosenfeld M, Chaudhuri G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis. Circ Res. 1999 ; 85 (4). 377-385
27. Yu HP, Hsieh YC, Suzuki T, et al. The PI3K/Akt pathway mediates the nongenomic cardioprotective effects of estrogen following trauma-hemorrhage. Ann Surg. 2007 ; 245 (6). 971-977
28. Node K, Kitakaze M, Kosaka H, Minamino T, Funaya H, Hori M. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. Circulation. 1997 ; 96 (6). 1953-1963
29. Ma Y, Qiao X, Falone AE, Reslan OM, Sheppard SJ, Khalil RA. Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell Physiol Biochem. 2010 ; 26 (3). 457-470
30. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004 ; 286 (2). R233 - R249
31. Serock MR, Wells AK, Khalil RA. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 ; 3 (3). 165-186
32. Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here?. Hypertension. 2004 ; 44 (6). 789-795
33. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 1988 ; 244 (1). 19-22
34. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 1994 ; 73 (13). 951-952
35. Isenovic E, Soskic S, Dungen HD, et al. Regulation of endothelial nitric oxide synthase in pathophysiological conditions. Cardiovasc Hematol Disord Drug Targets. 2011 ; 11 (2). 1-10
36. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003 ; 2: 2
37. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007 ; 87 (3). 905-931
38. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci. 2012 ; 67 (11). 1140-1152
39. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care. 2000 ; 23 (7). 912-918
40. Boon WC, Chow JD, Simpson ER. The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res. 2010 ; 181: 209-232
41. Lucas TF, Pimenta MT, Pisolato R, Lazari MF, Porto CS. 17beta-estradiol signaling and regulation of Sertoli cell function. Spermatogenesis. 2011 ; 1 (4). 318-324
42. Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. Pflugers Arch. 2010 ; 459 (6). 841-851
43. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci. 2009 ; 66 (15). 2405-2426
44. Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006 ; 58 (4). 773-781
45. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab. 2009 ; 20 (10). 477-482
46. McNeill AM, Kim N, Duckles SP, Krause DN, Kontos HA. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke. 1999 ; 30 (10). 2186-2190
47. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology. 2006 ; 147 (12). 5557-5563
48. Tepavcevic S, Koricanac G, Zakula Z, Milosavljevic T, Stojiljkovic M, Isenovic ER. Interaction between insulin and estradiol in regulation of cardiac glucose and free fatty acid transporters. Horm Metab Res. 2011 ; 43 (8). 524-530
49. Nilsson BO, Olde B, Leeb-Lundberg LM. G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br J Pharmacol. 2011 ; 163 (6). 1131-1139
50. Meyer MR, Prossnitz ER, Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol. 2011 ; 55 (1-3). 17-25
51. Filardo EJ, Quinn JA, Bland KI, Frackelton AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000 ; 14 (10). 1649-1660
52. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005 ; 307 (5715). 1625-1630
53. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005 ; 146 (2). 624-632
54. Thomas P, Alyea R, Pang Y, eyton C, Dong J, Berg AH. Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish. Steroids. 2010 ; 75 (8-9). 595-602
55. Chen CC, Ke WH, Ceng LH, Hsieh CW, Wung BS. Calcium- and phosphatidylinositol 3-kinase/Akt-dependent activation of endothelial nitric oxide synthase by apigenin. Life Sci. 2010 ; 87 (23-26). 743-749
56. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J Pharmacol Exp Ther. 2001 ; 299 (3). 818-824
57. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003 ; 284 (1). R1 - R12
58. Chen DB, Bird IM, Zheng J, Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology. 2004 ; 145 (1). 113-125
59. Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999 ; 9 (15). 845-848
60. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999 ; 399 (6736). 601-605
61. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004 ; 279 (7). 6190-6195
62. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of endothelium-derived vascular relaxant factor. Nature. 1984 ; 308 (5960). 645-647
63. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003 ; 54 (4). 469-487
64. Lincoln TM, Thompson M, Cornwell TL. Purification and characterization of two forms of cyclic GMP-dependent protein kinase from bovine aorta. J Biol Chem. 1988 ; 263 (33). 17632-17637
65. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993 ; 7 (2). 328-338
66. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2006 ; 86 (1). 1-23
67. Yao X, Huang Y. From nitric oxide to endothelial cytosolic Ca2+: a negative feedback control. Trends Pharmacol Sci. 2003 ; 24 (6). 263-266
68. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010 ; 459 (6). 793-806
69. Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008 ; 51 (3). 784-790
70. Mendoza MG, Robles HV, Romo E, Rios A, Escalante B. Nitric oxide-dependent neovascularization role in the lower extremity disease. Curr Pharm Des. 2007 ; 13 (35). 3591-3596
71. Kumar D, Branch BG, Pattillo CB, et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA. 2008 ; 105 (21). 7540-7545
72. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 1994 ; 356 (2-3). 295-298
73. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA. 2004 ; 101 (37). 13683-13688
74. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005 ; 115 (5). 1232-1240
75. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998 ; 101 (11). 2567-2578
76. Monteiro HP, Gruia-Gray J, Peranovich TM, de Oliveira LC, Stern A. Nitric oxide stimulates tyrosine phosphorylation of focal adhesion kinase, Src kinase, and mitogen-activated protein kinases in murine fibroblasts. Free Radic Biol Med. 2000 ; 28 (2). 174-182
77. Oliveira CJ, Schindler F, Ventura AM, et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic Biol Med. 2003 ; 35 (4). 381-396
78. Bernabe JC, Tejedo JR, Rincon P, et al. Sodium nitroprusside-induced mitochondrial apoptotic events in insulin-secreting RINm5F cells are associated with MAP kinases activation. Exp Cell Res. 2001 ; 269 (2). 222-229
79. Narang H, Dhariwala FA, Krishna M. Effect of nitric oxide donor and gamma irradiation on modifications of ERK and JNK in murine peritoneal macrophages. J Cell Commun Signal. 2007 ; 1 (3-4). 219-226
80. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev. 2002 ; 54 (4). 619-634
81. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol. 1998 ; 18 (2). 157-167
82. Cromheeke KM, Kockx MM, De Meyer GR, et al. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques. Cardiovasc Res. 1999 ; 43 (3). 744-754
83. Thomson L, Tenopoulou M, Lightfoot R, et al. Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation. 2012 ; 126 (20). 2392-2401
84. Vina J, Sastre J, Pallardo FV, Gambini J, Borras C. Role of mitochondrial oxidative stress to explain the different longevity between genders: protective effect of estrogens. Free Radic Res. 2006 ; 40 (12). 1359-1365
85. Arnal JF, Clamens S, Pechet C, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA. 1996 ; 93 (9). 4108-4113
86. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002 ; 90 (1A). 3F - 6F
87. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011 ; 109 (6). 687-696
88. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res. 1999 ; 43 (3). 532-541
89. Chen PF, Tsai AL, Berka V, Wu KK. Mutation of Glu-361 in human endothelial nitric-oxide synthase selectively abolishes l-arginine binding without perturbing the behavior of heme and other redox centers. J Biol Chem. 1997 ; 272 (10). 6114-6118
90. Sessa WC, Harrison JK, Barber CM, et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem. 1992 ; 267 (22). 15274-15276
91. Sindler AL, Fleenor BS, Calvert JW, et al. Nitrite supplementation reverses vascular endothelial dysfunction and large elastic artery stiffness with aging. Aging Cell. 2011 ; 10 (3). 429-437
92. Yang YM, Huang A, Kaley G, Sun D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol. 2009 ; 297 (5). H1829 - H1836
93. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol. 1997 ; 273 (1 pt 1). L119 - L126
94. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997 ; 81 (5). 885-892
95. Chambliss KL, Yuhanna IS, Mineo C, et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res. 2000 ; 87 (11). E44 - E52
96. Acconcia F, Ascenzi P, Bocedi A, et al. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell. 2005 ; 16 (1). 231-237
97. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun. 1999 ; 263 (1). 257-262
98. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol. 2002 ; 16 (5). 938-946
99. Kim KH, Moriarty K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids. 2008 ; 73 (9-10). 864-869
100. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem. 2003 ; 278 (4). 2118-2123
101. Kim KH, Bender JR. Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol. 2009 ; 308 (1-2). 3-8
102. Mineo C, Shaul PW. Circulating cardiovascular disease risk factors and signaling in endothelial cell caveolae. Cardiovasc Res. 2006 ; 70 (1). 31-41
103. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000 ; 407 (6803). 538-541
104. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000 ; 87 (8). 677-682
105. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997 ; 88 (4). 435-437
106. Peach MJ, Loeb AL, Singer HA, Saye J. Endothelium-derived vascular relaxing factor. Hypertension. 1985 ; 7 (3 pt 2). I94-100
107. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci. 1997 ; 811: 60-67
108. Kamata K, Nakajima M. Ca2+ mobilization in the aortic endothelium in streptozotocin-induced diabetic and cholesterol-fed mice. Br J Pharmacol. 1998 ; 123 (8). 1509-1516
109. Kobayashi T, Matsumoto T, Kamata K. The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models. J Smooth Muscle Res. 2005 ; 41 (6). 283-302
110. Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Physiol. 1994 ; 266 (3 pt 1). C628 - C636
111. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994 ; 45 (2). 598-604
112. Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci USA. 1999 ; 96 (26). 15133-15136
113. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Mol Cell Endocrinol. 2007 ; 265-266: 138-142
114. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol. 2010 ; 204 (2). 105-114
115. Carreau S, Bouraima-Lelong H, Delalande C. Estrogen, a female hormone involved in spermatogenesis. Adv Med Sci. 2012 ; 57 (1). 31-36
116. Taguchi K, Morishige A, Matsumoto T, Kamata K, Kobayashi T. Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation. Pflugers Arch. 2012 ; 464 (2). 205-215
117. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977 ; 265 (5589). 69-72
118. Pietras RJ, Szego CM. Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochem J. 1980 ; 191 (3). 743-760
119. Novella S, Laguna-Fernandez A, Lazaro-Franco M, et al. Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells. Mol Cell Endocrinol. 2013 ; 365 (1). 11-16
120. Sessa WC. Regulation of endothelial derived nitric oxide in health and disease. Mem Inst Oswaldo Cruz. 2005 ; 100 (suppl 1). 15-18
121. Khalil RA. Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2010 ; 8 (1). 29-46
122. Kublickiene K, Svedas E, Landgren BM, et al. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab. 2005 ; 90 (11). 6113-6122
123. Shafighi M, Fathi AR, Brun C, et al. Topical application of 17beta-estradiol (E2) improves skin flap survival through activation of endothelial nitric oxide synthase in rats. Wound Repair Regen. 2012 ; 20 (5). 740-747
124. Scarabin-Carre V, Canonico M, Brailly-Tabard S, et al. High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study. J Am Heart Assoc. 2012 ; 1 (3). e001388
125. Karim R, Mack WJ, Kono N, et al. Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS). J Clin Endocrinol Metab. 2013 ; 98 (4). E610 - E618
126. Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials. 2012 ; 7 (1). 47-70
127. Vieira CS, Martins WP, Fernandes JB, et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception. 2012 ; 86 (3). 268-275
128. Isenovic ER, Divald A, Milivojevic N, Grgurevic T, Fisher SE, Sowers JR. Interactive effects of insulin-like growth factor-1 and beta-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism. 2003 ; 52 (4). 482-487
129. Widder J, Pelzer T, von Poser-Klein C, et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension. 2003 ; 42 (5). 991-996
130. Nilsson BO, Ekblad E, Heine T, Gustafsson J. Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice. J Endocrinol. 2000 ; 166 (2). R5 - R9
131. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002 ; 90 (4). 413-419
132. Ross RL, Serock MR, Khalil RA. Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease. Curr Cardiol Rev. 2008 ; 4 (4). 309-322
133. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res. 2003 ; 36 (9). 1143-1158
134. Huang A, Sun D, Koller A. Kaley G. 17beta-estradiol restores endothelial nitric oxide release to shear stress in arterioles of male hypertensive rats. Circulation. 2000 ; 101 (1). 94-100
135. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA. 1992 ; 89 (23). 11259-11263
136. Nigro D, Fortes ZB, Scivotetto R, Carvalho MH. Simultaneous release of endothelium-derived relaxing and contracting factors induced by noradrenaline in normotensive rats. Gen Pharmacol. 1990 ; 21 (4). 443-446
137. Han Y, Li X, Zhou S, et al. 17ss-estradiol antagonizes the down-regulation of ERalpha/NOS-3 signaling in vascular endothelial dysfunction of female diabetic rats. PLoS One. 2012 ; 7 (11). e50402
138. Li CM, Dong XL, Fan XD, et al. Aqueous extract of danshen (Salvia miltiorrhiza Bunge) protects ovariectomized rats fed with high-fat diet from endothelial dysfunction. Menopause. 2013 ; 20 (1). 100-109
139. Westphal C, Schubert C, Prelle K, et al. Effects of estrogen, an ERalpha agonist and raloxifene on pressure overload induced cardiac hypertrophy. PLoS One. 2012 ; 7 (12). e50802
140. Hayashi T, Esaki T, Sumi D, Mukherjee T, Iguchi A, Chaudhuri G. Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism. Proc Natl Acad Sci USA. 2006 ; 103 (27). 10485-10490
141. Aicher BO, Haser EK, Freeman LA, et al. Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity (Silver Spring). 2012 ; 20 (10). 2057-2062
142. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 ; 79 (1). 8-15
143. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008 ; 263 (3). 256-273
144. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998 ; 101 (8). 1581-1590
145. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006 ; 98 (11). 1352-1364
146. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001 ; 7 (7). 853-857
147. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003 ; 278 (11). 9142-9149
148. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004 ; 113 (4). 569-581
149. Terasaka N, Yu S, Yvan-Charvet L, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest. 2008 ; 118 (11). 3701-3713
150. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011 ; 121 (7). 2693-2708
151. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006 ; 98 (1). 63-72
152. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006 ; 26 (5). 1144-1149
153. Noor R, Shuaib U, Wang CX, et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis. 2007 ; 192 (1). 92-99
154. Feng Y, Jacobs F, Van Craeyveld E, et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008 ; 28 (2). 278-283
155. Petoumenos V, Nickenig G, Werner N. High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med. 2009 ; 13 (11-12). 4623-4635
156. Müllera U, Matsuoa Y, Lauberd M, et al. Correlation between endothelial function measured by finger plethysmography in children and HDL-mediated eNOS activation - a preliminary study. Metabolism. 2013 ; 62 (5). 634-637
157. Loscalzo J. Molecular Mechanisms of Atherosclerosis. New York, USA: Taylor & Francis Group ; 2004: 111-174.
158. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010 ; 208 (1). 3-9
159. Kypreos KE, Gkizas S, Rallidis LS, Karagiannides I. HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol. 2013 ; 85 (11). 1575-1578
160. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005 ; 5 (2). 551-565
161. Bruce C, Chouinard RA, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998 ; 18: 297-330
162. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008 ; 372 (9634). 224-233
163. Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009 ; 30 (17). 2137-2146
164. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000 ; 20 (12). 2670-2676
165. Huang R, Silva RA, Jerome WG, et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol. 2011 ; 18 (4). 416-422
166. Segrest JP, Jones MK, Klon AE, et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem. 1999 ; 274 (45). 31755-31758
167. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002 ; 161 (2). 245-254
168. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000 ; 41 (9). 1481-1494
169. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004 ; 95 (8). 764-772
170. Kanji SS, Kuohung W, Labaree DC, Hochberg RB. Regiospecific esterification of estrogens by lecithin: cholesterol acyltransferase. J Clin Endocrinol Metab. 1999 ; 84 (7). 2481-2488
171. Ruiz-Sanz JI, Navarro R, Martinez R, et al. 17Beta-estradiol affects in vivo the low density lipoprotein composition, particle size, and oxidizability. Free Radic Biol Med. 2001 ; 31 (3). 391-397
172. Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest. 2003 ; 111 (10). 1579-1587
173. Badeau RM, Metso J, Tikkanen MJ, Jauhiainen M. High-density lipoprotein-associated 17beta-estradiol fatty acyl ester uptake by Fu5AH hepatoma cells: implications of the roles of scavenger receptor class B, type I and the low-density lipoprotein receptor. Biochim Biophys Acta. 2007 ; 1771 (10). 1329-1334
174. Badeau RM, Metso J, Wahala K, Tikkanen MJ, Jauhiainen M. Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17beta-estradiol fatty acyl esters. J Steroid Biochem Mol Biol. 2009 ; 116 (1-2). 44-49
175. Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, menopause, and early atherosclerosis in study of women's health across the nation heart women. Menopause. 2011 ; 18 (4). 376-384
176. Barrett-Connor E. Menopause, atherosclerosis, and coronary artery disease. Curr Opin Pharmacol. 2013 ; 13 (2). 186-191
177. van der Vorst EP, Vanags LZ, Dunn LL, Prosser HC, Rye KA, Bursill CA. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J. 2013 ; 27 (4). 1413-1425
178. Wu BJ, Chen K, Shrestha S, Ong KL, Barter PJ, Rye KA. High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1. Circ Res. 2013 ; 112 (2). 278-288